Transformation of mammalian cells by overexpressing H2O2-generating peroxisomal fatty acyl-CoA oxidase.

Peroxisome proliferators induce qualitatively predictable pleiotropic responses, including development of hepatocellular carcinomas in rats and mice despite the inability of these compounds to interact with and damage DNA directly. In view of the nongenotoxic nature of peroxisome proliferators, it has been postulated that hepatocarcinogenesis by this class of chemicals is due to a receptor-mediated process leading to transcriptional activation of H2O2-generating peroxisomal fatty acyl-CoA oxidase (ACOX) in liver. To test this hypothesis, we overexpressed rat ACOX in African green monkey kidney cells (CV-1 cells) under control of the cytomegalovirus promoter. A stably transfected CV-1 cell line overexpressing rat ACOX, designated CV-ACOX4, when exposed to a fatty acid substrate (150 microM linoleic acid) for 2-6 weeks, formed transformed foci, grew efficiently in soft agar, and developed adenocarcinomas when transplanted into nude mice. These findings indicate that sustained overexpression of H2O2-generating ACOX causes cell transformation and provide further support for the role of peroxisome proliferation in hepatocarcinogenesis induced by peroxisome proliferators.

Human acetyl-CoA carboxylase: characterization, molecular cloning, and evidence for two isoforms.

We have cloned and sequenced the cDNA coding for human HepG2 acetyl-CoA carboxylase (ACC; EC 6.4.1.2). The sequence has an open reading frame of 7038 bp that encode 2346 amino acids (M(r), 264,737). The C-terminal 2.6-kb sequence is very different from that recently reported for human ACC (Ha, J., Daniel, S., Kong, I.-S., Park, C.-K., Tae, H.-J. & Kim, K.-H. [1994] Eur. J. Biochem. 219, 297-306). Northern blot analysis revealed that the ACC mRNA is approximately 10 kb in size and that its level varies among the tissues tested. Evidence is presented to show that the human ACC gene is 200-480 kbp in size and maps to chromosome 17q12. We also provide evidence for the presence of another ACC-like gene with similarly sized mRNA but tissue-specific expression different from that of the ACC gene reported herein. That this second ACC-like gene encodes the 280-kDa carboxylase is not ruled out.

Crystallization of the C-terminal domain of the mouse brain cytosolic long-chain acyl-CoA thioesterase

The mammalian long-chain acyl-CoA thioesterase, the enzyme that catalyses the hydrolysis of acyl-CoAs to free fatty acids, contains two fused 4HBT (4-hydroxybenzoyl-CoA thioesterase) motifs. The C-terminal domain of the mouse long-chain acyl-CoA thioesterase (Acot7) has been expressed in bacteria and crystallized. The crystals were obtained by vapour diffusion using PEG 2000 MME as precipitant at pH 7.0 and 290 K. The crystals have the symmetry of space group R32 ( unit-cell parameters a = b = 136.83, c = 99.82 angstrom, gamma = 120 degrees). Two molecules are expected in the asymmetric unit. The crystals diffract to 2.4 angstrom resolution using the laboratory X-ray source and are suitable for crystal structure determination.

Étude de la physiopathologie des souris déficientes en 3-hydroxy-3-methylglutaryl CoA lyase (HL) : un modèle de la déficience humaine en HL

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

Les inhibiteurs de l'HMG-CoA réductase en prévention de la maladie d'Alzheimer : minimiser l'effet du biais d'indication

Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

Étude de la physiopathologie des souris déficientes en 3-hydroxy-3-methylglutaryl CoA lyase (HL) : un modèle de la déficience humaine en HL

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

Les inhibiteurs de l'HMG-CoA réductase en prévention de la maladie d'Alzheimer : minimiser l'effet du biais d'indication

Thèse numérisée par la Direction des bibliothèques de l'Université de Montréal.

Possible inhibition of hydroxy methyl glutaryl CoA reductase activity by nicotinic acid and ergosterol: as targeting for hypocholesterolemic action.

Objective: Coronary artery diseases including atherosclerosis is considered as commonest problem worldwide. Ergosterols are the main components of vegetable oils and nuts. The objective of this study was to evaluate the potential hypoplipidemic and hypocholesterolemic effects of ergosterol in combination with niacin in rats fed high fat diet (HFD). Methods: Eighty male albino rats were included in this study divided into two main groups: Group I: Normal rats fed standard diet treated with either niacin (8.5 mg /kg b.w) or ergosterol (100 mg/kg b.w) or both. Group II; rats fed HFD treated with either niacin (8.5 mg /kg b.w) or ergosterol (100 mg/kg b.w) or both The feeding and treatment lasted for 8 weeks. Results: A significant elevation in the levels of total cholesterol, triacylglycerol, VLDL-c, LDL-c and atherogenic factor (p<0.001) in rats fed on HFD compared with normal control while HDL-c was significantly reduced in HFD rats compared with control group. Supplementation of diet with niacin or ergosterol or combined exerts improvement in the studied parameters by lowering triacylglycerol, total cholesterol, LDL-c and atherogenic factor and elevate HDL-c near to the value of control. Niacin combined with ergosterol were effective in the reduction of hydroxy methyl glutaryl-CoA reducatase (HMGCoA) compared with control (p<0.001). The combined effect was more potent than individual alone. Conclusion: Utilization of niacin and ergosterol may prevent the hypercholesterolemia and incidence of coronary heart diseases. These functional foods act as nutriceutical as dyslipidemics.

Purificação e caracterização parcial de duas N-acetil-ß-hexosaminidases do Equinoderma marinho Echinometra lucunter

Two b-N-acetylhexosaminidases (F11 e F15) were purified from Echinometra lucunter gonads extracts. The purified enzymes were obtained using ammonium sulfate fractionation, followed by gel filtration chromatographies (Sephacryl S-200, Sephadex G-75 and Sephacryl S-200). The F11 fraction was purified 192.47 -fold with a 28.5% yield, and F15 fraction 85.41 -fold with a 32.3% yield. The molecular weights of the fractions were 116 kDa for F11 and 42 kDa for F15 using SDS-PAGE. In Sephacryl S-200, F15 was 84 kDa, indicating that it is a dimeric protein. When p-nitrophenyl-β-D-glycosaminide was used as substrate, we determined an apparent Km of 0.257 mM and Vmax of 0.704 for F11 and for F15 the Km was 0.235 mM and Vmax of 0.9 mM of product liberated by hour. Both enzymes have optimum pH and temperature respectively at 5.0 and 45 °C. The enzymes showed inhibition by silver nitrate, while the glucuronic acid was a potent activator. The high inhibition of F15 by N-etylmaleimide indicates that sulphydril groups are involved in the catalysis of synthetic substrate

Studio della sintesi del 2-acetil furano mediante chetonizzazione in fase vapore

La reazione tra due acidi carbossilici o esteri a dare un chetone, H2O e CO2 (chetonizzazione) è molto studiata per l’upgrading del bio-olio grezzo, perché permette di ridurne l’acidità ed il tenore di ossigeno aumentandone il potere calorifico. Tuttavia, con opportuni accorgimenti questa reazione potrebbe essere impiegata anche per la sintesi selettiva di chetoni asimmetrici ad alto valore aggiunto; un esempio è l’acetil-furano (AF), che trova applicazione come aroma nell’industria alimentare e come intermedio per la sintesi dell’antibiotico Cefuroxima. In questo lavoro di tesi la sintesi di AF mediante la chetonizzazione incrociata tra 2-metil furoato (MF) ed etil acetato (EA) oppure acido acetico (AA), è stata investigata in fase gassosa con catalizzatori eterogenei (ZrO2, CeO2 e un ossido misto Ce/Zr/O), come alternativa più sostenibile al processo di sintesi industriale di AF basato sull’acilazione di Friedel-Crafts del furano con anidride acetica in fase liquida in reattori batch. Uno screening iniziale dei tre catalizzatori (350 °C, τ = 1 s, stechiometrica MF/AA = 1 in alimentazione) ha dimostrato che ZrO2 è di gran lunga più attivo e selettivo degli altri materiali, e che la chetonizzazione incrociata tra MF e AA è di gran lunga più selettiva di quella tra MF ed EA. Tuttavia, in queste condizioni la omochetonizzazione di AA (reagente limitante) compete con la chetonizzazione incrociata riducendo la massima conversione di MF ottenibile; pertanto, il rapporto AA/MF è stato aumentato fino a 4 ed in queste condizioni è stato possibile ottenere una conversione di MF quantitativa e una resa in AF pari al 70 %. Infine, la versatilità di questa via sintetica è stata ampliata sintetizzando chetoni furanici con catene alifatiche più lunghe propanoil furano (PF, resa = 82 %) e butanoil furano (BF, resa = 69 %) mediante la chetonizzazione incrociata di MF con acido propionico (AP) ed acido butirrico (AB).

Ácido acetil-salicíclico em baixa dose: indicação para prevenção primária de doença cardiovascular em idosos e anemia associada

A doença cardiovascular (DCV), incluindo a doença coronariana e cerebrovascular são importantes causas de morte no Brasil e no mundo e na população idosa. O ácido acetilsalicílico (AAS) em baixas doses tem sido cada vez mais usado como antiagregante plaquetário. O objetivo deste trabalho foi estudar o uso do AAS para prevenção primária de doenças cardiovasculares em idosos e sua correlação com anemia ferropriva. Foi realizada uma revisão bibliográfica nas bases de dados Lilacs, Pubmed, Medline e Google scholar, considerando o período de 1998 a 2011. O AAS tem sido indicado em homens de 45 a 79 anos quando o risco de infarto agudo do miocárdio supera o risco de hemorragia gastrintestinal. Também reduz o risco de acidente vascular cerebral em mulheres de 55 a 79 anos e em idosos com fibrilação atrial crônica com contra-indicação para uso de anticoagulante oral. A indicação do uso do AAS deve ser baseada em avaliação individual, pesando benefícios e riscos de reações adversas. Outro fator importante é que o uso de AAS em baixas doses para prevenção de DCV aumenta o risco de úlcera péptica e sangramento gastrintestinal, sendo maior em idosos. Ainda não está claro se o uso deste medicamento para prevenção de DCV, sem hemorragia manifesta, causa anemia em idosos, sendo necessários mais estudos sobre este tema.

Reduced Insulin Clearance And Lower Insulin-degrading Enzyme Expression In The Liver Might Contribute To The Thrifty Phenotype Of Protein-restricted Mice.

Nutrient restriction during the early stages of life usually leads to alterations in glucose homeostasis, mainly insulin secretion and sensitivity, increasing the risk of metabolic disorders in adulthood. Despite growing evidence regarding the importance of insulin clearance during glucose homeostasis in health and disease, no information exists about this process in malnourished animals. Thus, in the present study, we aimed to determine the effect of a nutrient-restricted diet on insulin clearance using a model in which 30-d-old C57BL/6 mice were exposed to a protein-restricted diet for 14 weeks. After this period, we evaluated many metabolic variables and extracted pancreatic islet, liver, gastrocnemius muscle (GCK) and white adipose tissue samples from the control (normal-protein diet) and restricted (low-protein diet, LP) mice. Insulin concentrations were determined using RIA and protein expression and phosphorylation by Western blot analysis. The LP mice exhibited lower body weight, glycaemia, and insulinaemia, increased glucose tolerance and altered insulin dynamics after the glucose challenge. The improved glucose tolerance could partially be explained by an increase in insulin sensitivity through the phosphorylation of the insulin receptor/protein kinase B and AMP-activated protein kinase/acetyl-CoA carboxylase in the liver, whereas the changes in insulin dynamics could be attributed to reduced insulin secretion coupled with reduced insulin clearance and lower insulin-degrading enzyme (IDE) expression in the liver and GCK. In summary, protein-restricted mice not only produce and secrete less insulin, but also remove and degrade less insulin. This phenomenon has the double benefit of sparing insulin while prolonging and potentiating its effects, probably due to the lower expression of IDE in the liver, possibly with long-term consequences.

[adherence To Statin Treatment And Associated Factors In Female Users From The Unified Health System (sus)].

To identify the adherence rate of a statin treatment and possible related factors in female users from the Unified Health System. Seventy-one women were evaluated (64.2 ± 11.0 years) regarding the socio-economic level, comorbidities, current medications, level of physical activity, self-report of muscular pain, adherence to the medical prescription, body composition and biochemical profile. The data were analyzed as frequencies, Chi-Squared test, and Mann Whitney test (p<0.05). 15.5% of women did not adhere to the medical prescription for the statin treatment, whose had less comorbidities (p=0.01), consumed less quantities of medications (p=0.00), and tended to be younger (p=0.06). Those patients also presented higher values of lipid profile (CT: p=0.01; LDL-c: p=0.02). Musculoskeletal complains were not associated to the adherence rate to the medication. The associated factors to adherence of dyslipidemic women to statin medical prescription were age, quantity of comorbidities and quantity of current medication.

Decreased Expression Of Stem Cell Markers By Simvastatin In 7,12-dimethylbenz(a)anthracene (dmba)-induced Breast Cancer.

Simvastatin, a competitive inhibitor of HMG-CoA reductase widely used in the treatment and prevention of hyperlipidemia-related diseases, has recently been associated to in vitro anticancer stem cell (CSC) actions. However, these effects have not been confirmed in vivo. To assess in vivo anti-CSC effects of simvastatin, female Sprague-Dawley rats with 7,12-dimethyl-benz(a)anthracene (DMBA)-induced mammary cancer and control animals were treated for 14 days with either simvastatin (20 or 40 mg/kg/day) or soybean oil (N = 60). Tumors and normal breast tissues were removed for pathologic examination and immunodetection of CSC markers. At 40 mg/kg/day, simvastatin significantly reduced tumor growth and the expression of most CSC markers. The reduction in tumor growth (80%) could not be explained solely by the decrease in CSCs, since the latter accounted for less than 10% of the neoplasia (differentiated cancer cells were also affected). Stem cells in normal, nonneoplastic breast tissues were not affected by simvastatin. Simvastatin was also associated with a significant decrease in proliferative activity but no increase in cell death. In conclusion, this is the first study to confirm simvastatin anti-CSC actions in vivo, further demonstrating that this effect is specific for neoplastic cells, but not restricted to CSCs, and most likely due to inhibition of cell proliferation.